Search | Clinical Trials Finder

Conditions: HIV Infections
Interventions: Racivir, a non-nucleoside reverse transcriptase inhibitor; Drug
Lead sponsor: Pharmasset; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Columbia, South Carolina

Conditions: Glaucoma and Ocular Hypertension
Interventions: DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 12 Months and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 34
States / cities: Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more

Conditions: Pancreatic Cancer
Interventions: Rintatolimod; Drug
Lead sponsor: AIM ImmunoTech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 3
States / cities: Omaha, Nebraska • Canton, Ohio • Seattle, Washington

Conditions: Bacterial Infections
Interventions: KSP-1007, Placebo:0.9% sodium chloride, Meropenem; Drug · Other
Lead sponsor: Sumitovant Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo; Drug
Lead sponsor: Altavant Sciences GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions: Absorb BVS, XIENCE; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 98
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more

Conditions: Crohn's Disease
Interventions: Filgotinib, Placebo; Drug · Other
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 101
States / cities: Dothan, Alabama • Sun City, Arizona • Coronado, California + 82 more

Conditions: Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions: Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo; Genetic · Drug
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide once weekly, exenatide twice daily; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 41
States / cities: Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 38 more

Conditions: Healthy Volunteer
Interventions: TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Asthma
Interventions: Fexofenadine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Type2 Diabetes, Gastrointestinal Symptoms
Interventions: Pendulum Glucose Control formulation for T2D; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: GSK189075; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypercholesterolemia
Interventions: PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 74
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Asthma
Interventions: CHF 718 pMDI, Placebo pMDI, Beclomethasone Dipropionate (BDP); Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 610 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 134
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 111 more

Conditions: Active Psoriatic Arthritis
Interventions: BMS-986165 Placebo, BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab, Ustekinumab Placebo; Other · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 31
States / cities: Huntsville, Alabama • Covina, California • La Jolla, California + 27 more

Conditions: Healthy Volunteers
Interventions: FTX-101, Placebo; Drug
Lead sponsor: Find Therapeutics; Industry
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Healthy
Interventions: HM10760A or placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: US, California

Conditions: Coronary Artery Disease
Interventions: MEDI6012, Placebo SC, Placebo IV; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 8
States / cities: Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 5 more

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: ONO-2952, ONO-2952 Matching Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 48
States / cities: Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: CS0159 (Linafexor); Drug
Lead sponsor: Cascade Pharmaceuticals, Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 17
States / cities: Gardena, California • Huntington Park, California • Panorama City, California + 13 more

Conditions: HCV Infection
Interventions: GS-9450, GS-9450 Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more

Search by objective public record fields.

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects

Multiple-Ascending Dose in Japanese Patients Bridging Study

Absorb IV Randomized Controlled Trial

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma

Pendulum D2D Glucose Control for Adults With Type 2 Diabetes

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

SAD and MAD Study of FTX-101 in Healthy Male Subjects

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV